Plandai Biotechnology Inc.
Planda Biotechnology, Inc. (the Company ) and its subsidiaries focus on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. The company grows the green tea used in its products on a 3,000-hectare estate in the Mpumalanga region of South Africa.
$0.00
+$0.00 (+0.00%)
Price from 4 days ago
The business is unprofitable at the operating level (-9526.11% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 65.0% YoY. Margins deteriorated 6533.2pp alongside, both lines moving the wrong way.
ROIC dropped from -62.44% to -140.34%, capital efficiency is deteriorating. Negative free cash flow of -$4M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$169K
▼ -65.0% YoY
Net Income (TTM)
-$5M
▲ +37.2% YoY
Op. Margin
-1493.95%
▼ -6533.2pp YoY
ROIC
-9.69%
▼ -77.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▲ +4.1% YoY
Op. Cash Flow (TTM)
-$2M
▼ -4.3% YoY
Net Debt
$28M
Cash & Equiv.
$8K
3Y CAGR: +7.7%
Continue Research
SourceComputed from the 10-Q filed 17 Aug 2016, covering the period ending 31 Mar 2016, as reported to the SEC. Data last refreshed 25 Sept 2026. How this is calculated.
Price from market data, last close as of 15 Oct 2026. Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Plandai Biotechnology (PLPL) overvalued?
Plandai Biotechnology (PLPL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Plandai Biotechnology scores 30/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Plandai Biotechnology a high-quality business?+
Plandai Biotechnology scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,494.0% operating margin and a -9.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Plandai Biotechnology a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh PLPL's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.